Author:
Rao S,Starling N,Cunningham D,Benson M,Wotherspoon A,Lüpfert C,Kurek R,Oates J,Baselga J,Hill A
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Abubakr Y, Pautret V, Maurel J, Scheithauer W, Kroening H, Zubel A, Lutz M, Wong L, Sobrero A (2006) Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of 800 patients in a randomized phase III trial (EPIC). In American Society of Clinical Oncology Annual Meetings Proceedings Part 1, Vol. 24, No 18S (June 20 Supplement). pp 3556
2. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110–124
3. Amendt CMO, Peters M, Yezhelyev M, Jauch KW, Geissler E, Bruns CJ (2003) In vivo activity of humanised monoclonal anti-EGFR antibody EMD 72000 in combination with gemcitabine on growth of primary pancreatic tumours and metastases in an orthoptic nude mouse model. In American Association of Cancer Research, Vol. 44
4. Bier H, Hoffmann T, Haas I, van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46: 167–173
5. Burger AM, Kreysch HG, Schandelmaier K, Wirth G, Fiebig HH, Grell M (2003) The humanised monoclonal anti-EGFR antibody EMD 72000 potentially inhibits the growth of EGFR-expressing human tumour xenografts insensitive to chemotherapeutic drugs. In American Association for Cancer Research, Vol. 44, pp 5719
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献